The United States and Britain announced a deal on Monday to securezero tariffs on British pharmaceutical products and medical ...
Many PBMs are also finding their business at risk as pharma–PBM tension continues to intensify. We predict that this tension will continue in 2026, especially for companies with late-stage assets in ...
On 1 December, the fortunes of the UK pharma sector changed radically, with the UK Government becoming the first in the world ...
Advanced technologies in pharma manufacturing necessitate a redefinition of the Qualified Person's role, focusing on digital ...
Biotechnology leader Biocon is fully integrating Biocon Biologics, valuing it at $5.5 billion. The merger involves share ...
West Pharmaceutical Services is the winner of the Product Launches Award for Prefillable Syringe Systems in the 2025 ...
Suzhou Zion Pharma Technology Co Ltd. has identified KRAS inhibitors, in particular GTPase KRAS G12D mutant and/or G13D mutant, reported to be useful for the treatment of cancer.
94% of pharma are either running (43%), planning to launch in the next twelve months (30%) or exploring (21%) a DTP program Only 6% have no current plans for a DTP program The number one potential ...
Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing ...
Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.
In a dramatic change to Australian patent law, Australia's Full Federal Court has just held that patents for pharmaceutical formulations are not eligible for patent term extensions ( PTE ): Otsuka ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback